Alpha emitting nuclides for targeted therapy

Jasmine L Hatcher-Lamarre; Vanessa A Sanders; Mohammed Rahman; Cathy S Cutler; Lynn C Francesconi

doi:10.1016/j.nucmedbio.2020.08.004

Alpha emitting nuclides for targeted therapy

Nucl Med Biol. 2021 Jan:92:228-240. doi: 10.1016/j.nucmedbio.2020.08.004. Epub 2020 Sep 1.

Authors

Jasmine L Hatcher-Lamarre¹, Vanessa A Sanders¹, Mohammed Rahman², Cathy S Cutler¹, Lynn C Francesconi³

Affiliations

¹ Collider Accelerator Department, Brookhaven National Laboratory, USA.
² Chemistry Department, Hunter College of the City University of New York, USA.
³ Chemistry Department, Hunter College of the City University of New York, USA; Chemistry Department, Graduate Center of the City University of New York, USA. Electronic address: lfrances@hunter.cuny.edu.

Abstract

Targeted alpha therapy (TAT) is an area of research with rapidly increasing importance as the emitted alpha particle has a significant effect on inducing cytotoxic effects on tumor cells while mitigating dose to normal tissues. Two significant isotopes of interest within the area of TAT are thorium-227 and actinium-225 due to their nuclear characteristics. Both isotopes have physical half-lives suitable for coordination with larger biomolecules, and additionally actinium-225 has potential to serve as an in vivo generator. In this review, the authors will discuss the production, purification, labeling reactions, and biological studies of actinium-225 and thorium-227 complexes and clinical studies.

Keywords: Actinium-225; Alpha therapy; Radiolabeling; Thorium-227.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Alpha Particles / therapeutic use*
Animals
Humans
Isotope Labeling
Radiochemistry

Abstract

Publication types

MeSH terms

Grants and funding